Description

• Title:
  Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
• Creator:
  Jentkiewicz, Aleksander;
  Haj Obeid, Esmail;
  Ulrych, Jakub;
  Krupa, Jan;
  Malinowski, Maciej;
  Krasowski, Michał;
  Kalinowska, Alicja;
  Pietras, Wiktoria;
  Kozieł, Adrian;
  Kurek, Zofia
• Description:
  Introduction and Purpose: Obesity is an escalating global health challenge, affecting over 2 billion individuals worldwide, contributing to many challenges for healthcare providers such as cardiovascular disorders, cancers, and type 2 diabetes mellitus. There is a need for effective treatments targeting T2DM, and obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists developed originally for T2DM treatment, have emerged as key agents for weight loss. This review examines current evidence regarding efficacy, safety, and mechanisms of action of GLP-1 RAs, particularly semaglutide and tirzepatide in obesity and weight loss treatment.   Description of the State of Knowledge: GLP-1 receptor agonists modulate appetite, resulting in lower calory intake. Gastric emptying and insulin secretion are also affected by GLP-1 RAs. Clinical trials consistently demonstrate significant weight loss, positive action on cardiovascular risk and better glycemic control. All GLP-1 RAs have common side effects which are gastrointestinal disorders, and gallbladder-related issues, but their safety profiles are acceptable.  Summary: Available evidence recommends GLP-1 receptor agonists in type 2 diabetes mellitus and obesity treatment. Tirzepatide and semaglutide are two pharmacological agents which show best results in terms of weight loss.  Materials and Evidence: A literature review was conducted using the PubMed database for articles published from January 2016 to January 2024, supplemented by earlier foundational papers. After screening 121 abstracts, 51 full-text articles were assessed, and 30 were ultimately included.
• Object availability:
  free access
• Rights: https://creativecommons.org/licenses/by-nc-sa/4.0 ;
  Prawa autorskie (c) 2025 Aleksander Jentkiewicz, Esmail Haj Obeid, Jakub Ulrych, Jan Krupa, Maciej Malinowski, Michał Krasowski, Alicja Kalinowska, Wiktoria Pietras, Adrian Kozieł, Zofia Kurek
• Date:
  2025.02.06
• Type:
  info:eu-repo/semantics/article;
  info:eu-repo/semantics/publishedVersion
• Language:
  English
• Source:
  Journal of Education, Health and Sport; Vol. 78 (2025); 57712;
  Journal of Education, Health and Sport; Tom 78 (2025); 57712;
  2391-8306
• Format:
  application/pdf
• Publisher:
  Nicolaus Copernicus University, Toruń, Poland
• Relation: https://apcz.umk.pl/JEHS/article/view/57712/41410
• Subject:
  tirzepatide;
  semaglutide;
  weight loss;
  GLP-1 receptor agonists;
  obesity treatment;
  liraglutide;
  type 2 diabetes mellitus
• Identifier: https://apcz.umk.pl/JEHS/article/view/57712
• Data provider:
  Akademicka Platforma Czasopism
• Can I use it?:
  seek permission
• Type:
  text